Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Frontline Atezolizumab Benefit in NSCLC Sustained Across Biomarker-Driven Subgroups

April 17th 2018

Adding atezolizumab to chemotherapy and an angiogenesis inhibitor led to significant improvement in progression-free survival for patients with untreated advanced nonsquamous non-small cell lung cancer.

Expert Unveils Untapped Potential in Radiotherapy for NSCLC

April 17th 2018

Ashley A. Weiner, MD, PhD, discusses the expansions and limitations of radiotherapy in patients with non–small cell lung cancer and ongoing efforts to enhance administration and efficacy.

Frontline Nivolumab/Ipilimumab Reduces Progression Risk by 42% in TMB-High NSCLC

April 17th 2018

The combination of nivolumab and ipilimumab more than tripled the 1-year progression-free survival rate versus chemotherapy for treatment-naïve patients with non–small cell lung cancer with high tumor mutation burden.

Neoadjuvant Nivolumab Elicits Encouraging Pathologic Response Rate in Resectable NSCLC

April 16th 2018

Neoadjuvant treatment with nivolumab demonstrated a 45% major pathologic response rate in patients with resectable stage I to III non–small cell lung cancer irrespective of PD-L1 expression.

Dr. Ramalingam on the Significance of the FLAURA Trial in NSCLC

April 16th 2018

Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses the significance of the phase III results of the FLAURA trial, which explored osimertinib (Tagrisso) in the frontline setting for patients with EGFR-mutant non

Frontline Pembrolizumab Combo Significantly Improves Survival in NSCLC

April 16th 2018

Combining pembrolizumab (Keytruda) with standard chemotherapy in the frontline setting reduced the risk of death by over 50% in patients with nonsquamous non–small cell lung cancer without EGFR or ALK mutations.

Dr. Subbiah on Safety and Efficacy of BLU-667 in RET-Altered Solid Tumors

April 16th 2018

Vivek Subbiah, MD, associate medical director, Clinical Center for Targeted Therapy, assistant professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the safety and efficacy findings of BLU-667 in RET-altered solid tumors in an interview during the 2018 AACR Annual Meeting.

BLU-667 Shows Promise for Advanced Solid Tumors With RET Alterations

April 15th 2018

BLU-667, a next-generation tyrosine kinase inhibitor, appeared to be well-tolerated and had broad clinical benefit among patients with advanced, RET-altered solid tumors who progressed on prior therapies.

QoL Data Support Durvalumab Use in Locally Advanced NSCLC

April 14th 2018

Durvalumab treatment over 12 months had no negative effect on key symptoms of lung cancer, physical function, global health status, or quality of life in patients with locally advanced, unresectable stage III non–small cell lung cancer who have not progressed following concurrent chemoradiotherapy.

Dr. Yang on Resistance Mechanisms from Osimertinib in NSCLC

April 14th 2018

James CH Yang, MD, PhD, Professor of Medicine, Deputy Director, Department of Medical Oncology, National Taiwan University Hospital, Director, Cancer Research, Center National Taiwan University College of Medicine, discusses resistance mechanisms that develop from treatment with osimertinib (Tagrisso) and other EGFR tyrosine kinase inhibitors (TKIs). Yang discussed this in an interview during the 2018 European Lung Cancer Congress, which is a joint collaboration between ESMO and the IASLC.

Post-Progression Data Establishes Osimertinib as Frontline Standard of Care for EGFR-Mutant NSCLC

April 14th 2018

First-line treatment with osimertinib resulted in a clinically meaningful delay in time from randomization to second progression on subsequent treatment or death, establishing the agent as a new standard of care in the frontline setting for patients with EGFR-mutant non–small cell lung cancer.

Dr. Besse Discusses Challenges Facing Stage IV NSCLC

April 13th 2018

Benjamin Besse, MD, Institut Gustave Roussy, Villejuif, Paris Sud University, discusses challenges facing the treatment of patients with stage IV non

Dr. Reck on the Rationale of the IMpower150 Trial in NSCLC

April 13th 2018

Martin Reck, MD, Department of Thoracic Oncology, Lung Clinic Grosshansdorf, discusses the IMpower150 trial data for patients with non

Necitumumab/Abemaciclib Combo Fails in Stage IV NSCLC

April 13th 2018

A phase Ib study of necitumumab in combination with abemaciclib failed to meaningfully improve outcomes in patients with stage IV non–small cell lung cancer.

Osimertinib Prevents CNS Progression in Advanced NSCLC in a Real-World Setting

April 13th 2018

Patients with advanced non–small cell lung cancer and baseline central nervous system metastasis showed control of their CNS metastasis after receiving osimertinib in a real-world clinical setting.

Developments Expanding Frontline NSCLC Treatment

April 13th 2018

Thomas E. Stinchcombe, MD, discussea existing and emerging first-line regimens coming through the pipeline for the treatment of patients with non–small cell lung cancer.

Frontline Osimertinib Controls Symptoms for Patients With EGFR-Mutated NSCLC

April 13th 2018

Frontline treatment with osimertinib led to similar improvements in quality of life, including a clinically meaningful improvement in cough, compared with a standard of care EGFR TKIs for patients with advanced EGFR-mutant non–small cell lung cancer.

Dr. Perol Discusses Results of the ALEX Trial in ALK+ NSCLC

April 12th 2018

Maurice Perol, MD, medical oncologist, Centre Leon Berard, discusses the results of the ALEX trial in ALK-positive non–small cell lung cancer.

Dr. Garon Discusses the CheckMate-384 Study in NSCLC

April 12th 2018

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the CheckMate-384 study in non–small cell lung cancer.

Dr. Garassino on QoL Findings from the FLAURA Study in NSCLC

April 12th 2018

Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the quality of life findings from the FLAURA study in non–small cell lung cancer.